Inhibition of the mammalian target of rapamycin (mTOR) as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies - A review of the evidence

mTOR inhibition shows antiepileptogenic effects in tuberous sclerosis mouse models and limited clinical data; evidence remains preclinical and not definitive.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-17
DOI
https://doi.org/10.5281/zenodo.24306485
Primary Topic
Tuberous Sclerosis Complex Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inhibition of the mammalian target of rapamycin (mTOR) as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies - A review of the evidence

Deborah Iodice
Zenodo (CERN European Organization for Nuclear Research)
Tuberous Sclerosis Complex Research
article

Inhibition of the mammalian target of rapamycin (mTOR) as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies - A review of the evidence

Deborah Iodice
article en

Abstract

mTOR inhibition shows antiepileptogenic effects in tuberous sclerosis mouse models and limited clinical data; evidence remains preclinical and not definitive.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Tuberous Sclerosis Complex Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon